美国临床医生最喜欢用哪种哮喘生物药?

2019-11-22 不详 MedSci原创

从罗氏(Roche)和诺华(Novartis)的Xolair(奥马珠单抗:靶向IgE)到赛诺菲(Sanofi)和再生元的Dupixent(dupilumab,靶向IL-4和IL-13),以及阿斯利康(AstraZeneca)的Fasenra(benralizumab,靶向IL-5Rα)和葛兰素史克(GlaxoSmithKline)的Nucala(美泊利单抗,靶向IL-5),几种生物制剂正在争夺哮喘

从罗氏(Roche)和诺华(Novartis)的Xolair(奥马珠单抗:靶向IgE)到赛诺菲(Sanofi)和再生元的Dupixent(dupilumab,靶向IL-4和IL-13),以及阿斯利康(AstraZeneca)的Fasenra(benralizumab,靶向IL-5Rα)和葛兰素史克(GlaxoSmithKline)的Nucala(美泊利单抗,靶向IL-5),几种生物制剂正在争夺哮喘市场的份额。那临床医生更喜欢哪一种?

令人惊讶的是,没有明确的获胜者。SVBLeerink分析师Geoffrey Porges在与6位美国普通肺病学家交谈后于11月15日发表的一份报告中表示。

Porges指出,如果必须选出一名获胜者,那么"最主要的选择"似乎是Fasenra"由于给药方便",然后是Dupixent,"由于其给药范围更广,限制性更小,特别是在特应性患者中"。

在一次简短的调查中,Porges与四名目前共治疗1550名哮喘患者的肺科医师进行了合作,三名选择了Fasenra作为转诊的大多数哮喘患者的生物学用药,一名选择了Nucala。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=814547, encodeId=c8b881454e82, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:29:43 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375881, encodeId=a9593e588169, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Nov 27 06:23:13 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554799, encodeId=9a9a1554e99ea, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 07:34:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375705, encodeId=861c3e570559, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:07 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375704, encodeId=75023e57043d, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:02 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2020-08-28 14818eb4m67暂无昵称

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=814547, encodeId=c8b881454e82, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:29:43 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375881, encodeId=a9593e588169, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Nov 27 06:23:13 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554799, encodeId=9a9a1554e99ea, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 07:34:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375705, encodeId=861c3e570559, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:07 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375704, encodeId=75023e57043d, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:02 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-27 thm112988

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=814547, encodeId=c8b881454e82, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:29:43 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375881, encodeId=a9593e588169, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Nov 27 06:23:13 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554799, encodeId=9a9a1554e99ea, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 07:34:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375705, encodeId=861c3e570559, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:07 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375704, encodeId=75023e57043d, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:02 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=814547, encodeId=c8b881454e82, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:29:43 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375881, encodeId=a9593e588169, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Nov 27 06:23:13 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554799, encodeId=9a9a1554e99ea, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 07:34:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375705, encodeId=861c3e570559, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:07 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375704, encodeId=75023e57043d, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:02 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 14794e5bm67(暂无昵称)

    非常好的研究,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=814547, encodeId=c8b881454e82, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:29:43 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375881, encodeId=a9593e588169, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Nov 27 06:23:13 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554799, encodeId=9a9a1554e99ea, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Sun Nov 24 07:34:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375705, encodeId=861c3e570559, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:07 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375704, encodeId=75023e57043d, content=非常好的研究,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 23 08:42:02 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 14794e5bm67(暂无昵称)

    非常好的研究,学习了

    0

相关资讯

Environ Pollut:与哮喘、鼻炎和喘息相关的家庭环境和生活方式因素分析

哮喘和过敏性疾病的患病率自从2000年以来迅速增加。而关于家庭环境和生活方式因素与哮喘和过敏性疾病症状的相关性方面仍旧研究有限。最近,有研究人员在中国北京的2214名儿童中进行了代表性的分析。研究发现,许多环境和生活相关的因素与哮喘、鼻炎或者喘息相关,这些因素将哮喘、鼻炎或者喘息的可能性从-5.76% (95% CI: -7.74%到-3.79%)改变到了27.4% (95% CI: 16.6%到

World Allergy Organ J:过敏性鼻炎历史和哮喘风险研究

在一些研究中,过敏性鼻炎被质疑是哮喘的一个风险因子,但是该相关性并没有很好的证实。最近,有研究人员通过一个系统的回顾和元分析提出了过敏性鼻炎与哮喘风险相关性的证据。研究人员在Medline、Scopus、ISI会议记录数据库和其他数据库中进行了搜索,截止时间为2019年2月,之后进行人工检索来鉴定报道相对风险评估和过敏性鼻炎和哮喘相关性置信区间的案例对照和群体研究,研究人员排除了代表性的额研究。研

J Aller Cl Imm-Pract:静脉注射瑞利珠单抗治疗口服糖皮质激素依赖型哮喘的疗效

由此可见,与安慰剂相比,接受瑞利珠单抗治疗的患者新开SCS处方数较少,并且全身性皮质类固醇激素负担较低。

Immun:为什么儿童哮喘患病率比成人高?可能是多巴胺的影响

11月19日发表于《Immunity》杂志的一项研究成果显示,产生神经递质多巴胺的神经元能够与T细胞进行通讯,以增强幼鼠肺部的过敏性炎症,但老年小鼠的肺部却未见该现象,这些发现有可能解释为什么儿童哮喘患病率比成人高。

Chiesi Group宣布其单吸入器三联疗法治疗严重哮喘的两项III期阳性数据

Chiesi Group分析了两项三期临床研究TRIMARAN和TRIGGER的数据,评估了在成人哮喘患者中,超细制剂单吸入三联疗法与超细制剂吸入皮质类固醇(ICS)和长效β2激动剂(LABA)相比的疗效和安全性。

Am J Resp Crit Care:超越BMI的范围去理解肥胖哮喘

儿童哮喘和肥胖症对公共卫生构成重大挑战,影响到世界各地数百万儿童。在美国约9%的儿童患有哮喘,约30%超重或肥胖。大量流行病学证据表明,肥胖是儿童哮喘和哮喘发病率增加的一个危险因素。